Cadrenal Therapeutics (CVKD) Acquires VLX-1005 for HIT Treatment in $200,000 Deal
Cadrenal Therapeutics (CVKD) acquired VLX-1005 for Heparin-Induced Thrombocytopenia treatment in a $200,000 asset purchase.
$CVKD
Cadrenal Therapeutics (CVKD) Acquires VLX-1005 for HIT, Bolsters Pipeline with $3.9M Cash
Cadrenal Therapeutics (CVKD) acquired VLX-1005 for HIT from Veralox for $200,000, with $3.9M cash on hand as of Sept 2025.